UNLABELLED: We investigated bone turnover and its restoration in a large number of patients in the active phase and after cure of endogenous Cushing's syndrome. Furthermore, the usefulness of serum osteocalcin and collagen breakdown products as potential markers of active Cushing's syndrome was also evaluated. INTRODUCTION: Suppressed bone formation is one of the most characteristic features of Cushing's syndrome (CS). Despite numerous previous reports, many aspects of the disturbed bone metabolism of these patients are unexplored. In this study, we investigated the time course of bone marker changes after the cure of CS as well as correlations between bone markers and serum cortisol concentrations. METHODS: Eighty-seven patients with CS were studied. Patients were followed up to 48 months after surgical cure. Serum osteocalcin (OC) and collagen breakdown products (CTX) were measured with immunochemiluminescence method and compared to the results of 161 healthy controls. RESULTS: OC showed a negative, while CTX displayed a positive correlation with serum cortisol. Patients with diabetes mellitus and myopathy had significantly lower serum OC levels compared to those without these complications. The area under the curve of OC obtained by receiver-operating characteristics analysis for the discrimination of patients with CS from healthy controls was 0.9227. Postoperative OC increased rapidly from the first few days or weeks reaching its maximum at the sixth month and remained stable after the 24th postoperative month. CONCLUSIONS: Our study demonstrated significant correlations between serum cortisol and both bone formation and resorption markers in the active phase of CS. We propose that OC may serve as a sensitive biologic marker of glucocorticoid activity in endogenous CS during its active phase and it may reflect the clinical cure of the disease.
UNLABELLED: We investigated bone turnover and its restoration in a large number of patients in the active phase and after cure of endogenous Cushing's syndrome. Furthermore, the usefulness of serum osteocalcin and collagen breakdown products as potential markers of active Cushing's syndrome was also evaluated. INTRODUCTION: Suppressed bone formation is one of the most characteristic features of Cushing's syndrome (CS). Despite numerous previous reports, many aspects of the disturbed bone metabolism of these patients are unexplored. In this study, we investigated the time course of bone marker changes after the cure of CS as well as correlations between bone markers and serum cortisol concentrations. METHODS: Eighty-seven patients with CS were studied. Patients were followed up to 48 months after surgical cure. Serum osteocalcin (OC) and collagen breakdown products (CTX) were measured with immunochemiluminescence method and compared to the results of 161 healthy controls. RESULTS:OC showed a negative, while CTX displayed a positive correlation with serum cortisol. Patients with diabetes mellitus and myopathy had significantly lower serum OC levels compared to those without these complications. The area under the curve of OC obtained by receiver-operating characteristics analysis for the discrimination of patients with CS from healthy controls was 0.9227. Postoperative OC increased rapidly from the first few days or weeks reaching its maximum at the sixth month and remained stable after the 24th postoperative month. CONCLUSIONS: Our study demonstrated significant correlations between serum cortisol and both bone formation and resorption markers in the active phase of CS. We propose that OC may serve as a sensitive biologic marker of glucocorticoid activity in endogenous CS during its active phase and it may reflect the clinical cure of the disease.
Authors: Mohamed B Elamin; M Hassan Murad; Rebecca Mullan; Dana Erickson; Katherine Harris; Sarah Nadeem; Robert Ennis; Patricia J Erwin; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-03-11 Impact factor: 5.958
Authors: S Scommegna; J P Greening; H L Storr; K M Davies; N J Shaw; J P Monson; A B Grossman; M O Savage Journal: J Endocrinol Invest Date: 2005-03 Impact factor: 4.256
Authors: Mark S Cooper; Holly E Syddall; Caroline H D Fall; Peter J Wood; Paul M Stewart; Cyrus Cooper; Elaine M Dennison Journal: Clin Endocrinol (Oxf) Date: 2005-06 Impact factor: 3.478
Authors: A R Hermus; A G Smals; L M Swinkels; D A Huysmans; G F Pieters; C F Sweep; F H Corstens; P W Kloppenborg Journal: J Clin Endocrinol Metab Date: 1995-10 Impact factor: 5.958
Authors: L Füto; J Toke; A Patócs; A Szappanos; I Varga; E Gláz; Z Tulassay; K Rácz; M Tóth Journal: Osteoporos Int Date: 2007-11-28 Impact factor: 4.507
Authors: A Piovesan; M Terzolo; G Reimondo; A Pia; A Codegone; G Osella; A Boccuzzi; P Paccotti; A Angeli Journal: Horm Metab Res Date: 1994-05 Impact factor: 2.936
Authors: K Mészáros; G Karvaly; Z Márta; B Magda; J Tőke; N Szücs; M Tóth; K Rácz; A Patócs Journal: J Endocrinol Invest Date: 2017-08-16 Impact factor: 4.256
Authors: A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao Journal: Osteoporos Int Date: 2013-12-06 Impact factor: 4.507
Authors: Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Alexander G Solodovnikov; Liudmila Y Rozhinskaya; Larisa K Dzeranova; Ivan I Dedov Journal: Bonekey Rep Date: 2016-06-15
Authors: Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov Journal: Osteoporos Int Date: 2013-01-29 Impact factor: 4.507
Authors: E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body Journal: Osteoporos Int Date: 2016-03-30 Impact factor: 4.507